Injektionslösung
Sponsors
Leap Therapeutics Inc., Farmalider S.A., Janssen - Cilag International, Askbio Inc., Universitair Ziekenhuis Gent
Conditions
Acute mesenteric ischemiaAcute painAdvanced or Metastatic Colorectal CancerColorectal Cancer and Breast CancerColorectal cancerGastric AdenocarcinomaGastric cancerGastroEsophageal Cancer
Phase 1
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer
RecruitingCTIS2023-506517-22-00
Start: 2022-08-31Target: 37Updated: 2025-12-12
A Phase 1a/1b Study of ELVN-002 Combined with Trastuzumab in Advanced Stage HER2+ Solid tumors, and ELVN-002 Combined with Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast Cancer
Active, not recruitingCTIS2023-509716-29-00
Start: 2024-09-23Target: 156Updated: 2025-11-24
NEOadjuvant chemotherapy only compared with standard treatment for Locally Advanced Rectal cancer: a randomized phase II trial
Active, not recruitingCTIS2024-517748-76-00
Start: 2016-11-14Target: 124Updated: 2024-10-08
NeoART – A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therapies for HER2+, resectable esophagogastric adenocarcinoma
RecruitingCTIS2024-518841-12-00
Start: 2025-03-25Target: 39Updated: 2025-12-01
A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5764227 in combination with Standard of Care (SoC) or other agents in Participants with Advanced Solid Tumors
RecruitingCTIS2025-522274-37-00
Start: 2025-12-03Target: 15Updated: 2025-11-21
Phase 2
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)
CompletedCTIS2023-504940-32-00
Start: 2023-10-13End: 2025-02-17Target: 15Updated: 2024-09-26
The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group
RecruitingCTIS2024-512980-29-00
Start: 2023-08-28Target: 32Updated: 2025-10-22
DANTE / FLOT8
A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (MO30039/MO43340)– The IKF-DANTE Trial
A Trial of AIO in collaboration with SAKK
Active, not recruitingCTIS2024-514945-12-00
Start: 2018-09-03Target: 624Updated: 2025-12-11
(ASK-PD5-CS201) A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults with Moderate Stage Parkinson’s Disease
RecruitingCTIS2023-506519-16-00
Start: 2025-04-11Target: 55Updated: 2026-01-27
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma - A phase II trial of the AIO study group – PHERFLOT
Active, not recruitingCTIS2024-513610-34-00
Start: 2023-02-13Target: 30Updated: 2025-06-30
Organ preservation in locally advanced rectal cancer by
radiochemotherapy followed by consolidation chemotherapy. A
prospective phase II pilot trial of the German Rectal Cancer
Study Group
CompletedCTIS2024-517928-19-00
Start: 2018-04-17End: 2025-07-30Target: 89Updated: 2025-02-25
FUTURE platform trial –
A phase II platform trial of futibatinib in combination with (chemo)immunotherapy in colorectal cancer and other solid tumor entities
RecruitingCTIS2024-517573-24-00
Start: 2025-12-08Target: 33Updated: 2025-12-02
Phase 3
Phase III, double-blind, randomised, placebo- and active treatment-controlled clinical trial to evaluate the analgesic efficacy and safety of a combination of ibuprofen (arginate)-tramadol hydrochloride 400-37.5 mg, administered intravenously to patients with acute severe postoperative pain.
RecruitingCTIS2023-505687-11-00
Start: 2024-02-06Target: 216Updated: 2025-09-09
ORal antibiotics In Acute Mesenteric Ischemia: a multicenter randomized
RecruitingCTIS2023-508249-42-00
Start: 2025-01-31Target: 196Updated: 2024-07-23
Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients, A randomized phase III trial of the German Rectal Cancer Study Group
Active, not recruitingCTIS2024-511577-29-01
Start: 2020-03-13Target: 688Updated: 2026-01-26
A contrast medium sparing strategy using automated Carbon Dioxide Injection during PERIpheral vascular interventions for PREVENTion of Major Adverse Kidney Events (MAKE): the PeriPREVENT randomized controlled trial
RecruitingCTIS2024-512876-37-00
Start: 2025-04-11Target: 1960Updated: 2025-11-06
Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy - The Phase II/III RAMIRIS STUDY
Active, not recruitingCTIS2024-512934-14-00
Start: 2016-11-07Target: 319Updated: 2025-06-23
A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) With No Distant Metastases
Not yet recruitingCTIS2025-523017-28-00
Target: 30Updated: 2026-04-03
Phase 4
PPOS and CFA for elective Freeze-All ovarian stimulation cycles: a prospective cross-over study
RecruitingCTIS2023-506694-35-00
Start: 2025-01-24Target: 60Updated: 2025-04-09
Intubation Conditions in Morbidly Obese Patients with Rapid Sequence Induction: A Comparative Study of Rocuronium Dosing based on Ideal vs. Real Body Weight
WithdrawnCTIS2025-520977-37-00
Target: 182Updated: 2025-11-12